ArticleTobacco induced diseases2025
An analysis of the global, regional, and national epidemiology and trends of Alzheimer's disease and other dementias linked to smoking from 1990 to 2021 and projections to 2050.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis research assesses the smoking-related impact on Alzheimer's disease and other dementias (ADOD), analyzing variables such as sex, age, sociodemographic index (SDI), region, and country from 1990 to 2021, with forecasts to 2050.
methodsUsing data from the Global Burden of Disease Study 2021, we examined smoking-related ADOD trends from 1990 to 2021, focusing on deaths, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) by age, sex, SDI, location, and country. We quantified trends with estimated annual percentage changes and used decomposition analysis to evaluate the effects of population growth, aging, and epidemiological shifts. A frontier analysis identified improvement areas and disparities among countries by development status. Time series prediction models were used to predict smoking-attributable ADOD trends from 2022 to 2050, considering population profiles.
resultsBetween 1990 and 2021, there was an observable upward trend in deaths, DALYs, YLLs, and YLDs. In 2021, the burden of smoking-attributable age-related diseases predominantly impacted males across all age groups. Females, however, experienced a more pronounced reduction in age-standardized rates (ASR) of deaths, DALYs, YLLs, and YLDs compared to their male counterparts. The data from 2021 reveal that ASR of deaths, DALYs, and YLLs increased with age, reaching a peak among individuals aged ≥95 years. These ASR trends were consistent across genders, although higher rates were observed in males than in females. In 2021, the high-middle SDI region recorded the highest ASR of deaths, DALYs, YLLs, and YLDs. All five SDI regions experienced declines in ASR of deaths, DALYs, YLLs, and YLDs, with the high-SDI region demonstrating the most significant reductions in the estimated annual percentage change (EAPC). Decomposition analyses suggested that population growth was the primary factor contributing to the increase in overall deaths.
conclusionsFrom 1990 to 2021, there was an increase in deaths, DALYs, YLLs, and YLDs attributable to smoking-related ADOD, with projections indicating a continued rise globally until 2050. The burden of disease is mainly caused by males and middle-aged and elderly people, which should be given sufficient attention. Understanding epidemiological factors is crucial for designing effective, tailored interventions to mitigate the global burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.